GLP-1 based therapies and disease course of inflammatory bowel disease
patent issued, the USPTO held that the entire period from the RCE filing to the NO IDS filing (646 days) constituted applicant delay, which it deducted from over 2,000 days of USPTO delay that occurred during prosecution
Pineal gland regulation: The tetrapeptide modulates melatonin synthesis in the pineal gland, potentially restoring age-related declines in melatonin production that contribute to disrupted circadian rhythms and reduced antioxidant defense
Novo Nordisk is first out of the gate with an obesity pill that uses semaglutide, the same active ingredient found in Wegovy and Ozempic
AstraZeneca Lead assets: Elecoglipron, an oral GLP-1RA candidate Metabolic focus: Obesity, overweight, type 2 diabetes and cardiometabolic disease AstraZeneca is developing elecoglipron as a once-daily GLP-1RA pill for obesity and type 2 diabetes
Diabetes and endocrine disorders (hyperthyroidism/hypothyroidism) as risk factors for atrial fibrillation
.png)
